ArticleNutrients2025
Taxifolin as a Therapeutic Potential for Weight Loss: A Retrospective Longitudinal Study.
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Integrative network pharmacology and molecular modelling identify taxifolin as a potential modulator of melatonin receptor MT1 in mood disorders.Molecular diversity · 2026Article
- Taxifolin Inhibits Invasion and Endovascular Differentiation of Extravillous Trophoblast HTR-8/SVneo Cells.Cells · 2026Article
- Dihydroquercetin in Obesity and Prediabetes: Case Report and Insights from Molecular Modeling.International journal of molecular sciences · 2026Article
- Major phenolic compounds in Korean red pine (Food science and biotechnology · 2026Review
- Exploring the therapeutic potential of naturally occurring taxifolin, a dietary flavonoid: an updated comprehensive review.Frontiers in pharmacology · 2026Review
- Dihydroquercetin in Weight Control: Systematic Review and Meta-Analysis of Preclinical Studies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Taxifolin for prevention of COGnitive impairment (T-COG trial): a study protocol for a randomized, double-blind, placebo-controlled trial.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND/
objectivesThe current approach to obesity care, which primarily focuses on weight loss, is often insufficient because of the challenges in maintaining long-term results. Therefore, novel, safe, and sustainable medications for obesity are highly anticipated. Taxifolin, a natural bioactive flavonoid, was found to exert pleiotropic protective effects against various diseases. Our experimental
methodsA retrospective longitudinal study was conducted on participants who consistently monitored their body weight during routine clinic visits between January 2021 and July 2021. Body weight changes of the patients who received 300 mg/day of taxifolin were compared with those of patients who did not receive taxifolin.
resultsThe study enrolled a total of 62 patients: 36 received taxifolin and 26 did not receive taxifolin. Long-term intake of taxifolin showed greater weight loss than those not receiving taxifolin over a mean follow-up of 176.1 and 177.7 days, respectively (-1.6 vs. -0.3 kg;
conclusionsLong-term daily oral intake of taxifolin may safely and sustainably prevent or manage obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.